SHE SET THE FORMULARY. THE REBATES WENT UP. THE PATIENTS PAID LIST.

In January 2018, a decision made by CHS set the insulin formulary that affected millions of patients, where the preferred tier determined the cost between forty-five and a hundred and eighteen dollars. The alarming statistic was that while list prices tripled, the net prices received by manufacturers barely changed, leading to a crisis in insulin affordability.